Skip to main content
. 2020 Nov 23;10:563407. doi: 10.3389/fonc.2020.563407

Table 2.

First line therapy for patients with BRAFV600E mutated colorectal cancer.

Regimen Partial response Stable disease Progression disease mPFS (months)
Bevacizumab + FOLFOXIRI (N = 11) 6 3 2 8.8
Bevacizumab + FOLFOX/FOLFIRI/XELOX (N = 9) 2 5 2 9.1
FOLFOXIRI/FOLFOX/FOLFIRI/XELOX (N = 19) 4 8 7 4.6
Cetuximab + FOLFOX/FOLFIRI (N = 2) 0 2 0 4.3